PBA
VRDN icon

Paradigm Biocapital Advisors’s Viridian Therapeutics VRDN Stock Holding History

Paradigm Biocapital Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.6M Buy
3,148,893
+1,705,791
+118% +$50.7M 1.26% 22
2025
Q4 		$44.9M Sell
1,443,102
-1,166,251
-45% -$32M 1.15% 22
2025
Q3 		$56.3M Sell
2,609,353
-132,223
-5% -$2.38M 1.6% 19
2025
Q2 		$38.3M Buy
2,741,576
+646,497
+31% +$8.77M 1.64% 19
2025
Q1 		$28.2M Buy
2,095,079
+275,000
+15% +$4.68M 1.29% 20
2024
Q4 		$34.9M Sell
1,820,079
-1,075,610
-37% -$23.4M 1.21% 21
2024
Q3 		$65.9M Sell
2,895,689
-660
-0% -$10.8K 2.23% 14
2024
Q2 		$37.7M Sell
2,896,349
-2,135,071
-42% -$29.6M 1.44% 22
2024
Q1 		$88.1M Buy
5,031,420
+236,932
+5% +$4.59M 3.1% 15
2023
Q4 		$104M Buy
4,794,488
+1,112,741
+30% +$17.6M 4.89% 7
2023
Q3 		$56.5M Buy
3,681,747
+1,266,491
+52% +$24.2M 3.83% 12
2023
Q2 		$57.5M Buy
2,415,256
+329,558
+16% +$8.45M 4.44% 8
2023
Q1 		$53.1M Buy
2,085,698
+334,531
+19% +$10.7M 5.03% 8
2022
Q4 		$51.2M Buy
1,751,167
+114,956
+7% +$2.65M 6% 6
2022
Q3 		$33.6M Buy
1,636,211
+329,642
+25% +$5.93M 4.47% 9
2022
Q2 		$15.1M Buy
1,306,569
+50,518
+4% +$679K 3.01% 13
2022
Q1 		$23.2M Buy
1,256,051
+47,000
+4% +$903K 6.14% 6
2021
Q4 		$23.9M Buy
+1,209,051
New +$22.5M 6.83% 4

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Paradigm Biocapital Advisors's VRDN Position: Q1 2026 in Review

Paradigm Biocapital Advisors increased its Viridian Therapeutics (VRDN) stake by 118% in Q1 2026, buying an estimated $50.7M and bringing the position to 3,148,893 shares worth $61.6M. The position accounts for 1.26% of the portfolio, ranked #22.

Paradigm Biocapital Advisors first reported a position in VRDN in Q4 2021 and has held it in 18 quarters since. The position peaked at $104M in Q4 2023. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Paradigm Biocapital Advisors held 3,148,893 shares of Viridian Therapeutics worth $61.6M as of Q1 2026.
  • Paradigm Biocapital Advisors bought 1,705,791 Viridian Therapeutics shares in Q1 2026, an estimated $50.7M.
  • Viridian Therapeutics made up 1.26% of Paradigm Biocapital Advisors's portfolio in Q1 2026, its #22 holding.
  • Paradigm Biocapital Advisors first reported a position in Viridian Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Paradigm Biocapital Advisors's Viridian Therapeutics position peaked at $104M in Q4 2023.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.